There was no significant effect of anti-drug antibodies on the pharmacokinetics of tislelizumab-jsgr. The effect of anti-drug antibodies on pharmacodynamics, safety, or effectiveness of tislelizumab-jsgr has …

Feb 9, 2025 · Tryngolza package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

TRYNGOLZA® (olezarsen) is an FDA-approved treatment in adults with FCS as an adjunct to diet. See Safety & Full Prescribing Information.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRYNGOLZA safely and effectively. See full prescribing information for TRYNGOLZA.

Dec 11, 2025 · Tevimbra package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEVIMBRA safely and effectively. See full prescribing information for TEVIMBRA. …

Tislelizumab is approved in the EU for the treatment of ESCC, G/GEJ and three non-small cell lung cancer (NSCLC) indications. Tislelizumab is under regulatory review for extensive-stage small cell …

Dosage modifications for TEVIMBRA for adverse reactions that require management different from these general guidelines are summarized in Table 2. Refer to the respective Prescribing Information …

The data below reflect information for significant adverse drug reactions for tislelizumab as monotherapy in clinical studies. Details for the significant adverse reactions for tislelizumab when given in …

Dec 2, 2025 · In some patients with NSCLC, Tevimbra can be given before (neoadjuvant treatment) and after (adjuvant treatment) surgery. Depending on the cancer being treated, Tevimbra can be used on …